Related Experiment Videos
Thymic carcinoids in multiple endocrine neoplasia-type 1
S Hirai1, Y Hamanaka, N Mitsui
1Department of Thoracic Surgery, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minami-ku, Hiroshima 734-8530, Japan.
The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai Zasshi
|September 13, 2001
Summary
Multiple endocrine neoplasia type 1 (MEN1) patients with thymic carcinoids benefit from early, aggressive surgical thymectomy. Complete tumor excision and lymph node dissection offer the best survival outcomes, complemented by genetic and radiological therapies.
Area of Science:
- Endocrinology
- Thoracic Surgery
- Oncology
Background:
- Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic disorder associated with various endocrine tumors.
- Thymic carcinoids are uncommon manifestations of MEN1, often presenting with a poor prognosis.
Observation:
- A case study of a 45-year-old male with MEN1 and thymic carcinoids.
- The patient underwent an extended total thymectomy via median sternotomy, including mediastinal lymph node dissection and fibroadipose tissue resection.
Findings:
- Aggressive surgical resection, including complete tumor excision with peripheral tissue and lymph node removal, is currently the most effective treatment for MEN1-associated thymic carcinoids.
- Radiotherapy and chemotherapy show limited efficacy in prolonging survival for these rare tumors.
Implications:
- Early-stage thymectomy, combined with genetic and radiological treatments, may improve outcomes for MEN1 patients with thymic carcinoids.
- This aggressive surgical approach represents the current standard of care for managing these challenging neuroendocrine tumors.